ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023
Improved multimodal prediction of progression from MCI to Alzheimer's disease combining genetics with quantitative brain MRI and cognitive measures.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- FastSurfer-Based Brain Morphometry and Machine-Learning Classification Across the Alzheimer's Disease Spectrum.Brain sciences · 2026Article
- An AI-Health infrastructure for the Nordic region: technical foundations, data assets, and a roadmap for deployment.Nature medicine · 2026Article
- Sleep complaints and genetic risk of Alzheimer's disease in older women: associations with memory and tau deposition.The journal of prevention of Alzheimer's disease · 2026Article
- Robust Longitudinal Dementia Prediction under Systemic Missingness via Hierarchical Fusion and Test-Time Adaptation.medRxiv : the preprint server for health sciences · 2026Article
- Artificial intelligence in geriatric healthcare: a scoping review.BMC geriatrics · 2026Article
- Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Neuroimaging Epicenters as Vulnerable Nodes in Plasma p-tau217/Aβ42-Positive Alzheimer's Disease.Research (Washington, D.C.) · 2026Article
- Neurotransmitter-based machine-learning model for distinguishing Alzheimer's disease and mild cognitive impairment.The Journal of international medical research · 2026Article
- Predicting Future Brain Atrophy Based on Longitudinal MRI.medRxiv : the preprint server for health sciences · 2025Article
- Cross-Dataset Evaluation of Dementia Longitudinal Progression Prediction Models.Human brain mapping · 2025Article
- Cross-dataset Evaluation of Dementia Longitudinal Progression Prediction Models.medRxiv : the preprint server for health sciences · 2025Article
- Long COVID-related blood-brain barrier breakdown and microstructure in older adults are modified by sex and Alzheimer's disease genetic risk.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Dynamics of Cognitive Impairment in MCI Patients over a Three-Year Period: The Informative Role of Blood Biomarkers, Neuroimaging, and Genetic Factors.Diagnostics (Basel, Switzerland) · 2024Article
- Prediction of conversion from mild cognitive impairment to Alzheimer's disease and simultaneous feature selection and grouping using Medicaid claim data.Alzheimer's research & therapy · 2024Article
- Sex differences in the relationship between depression and Alzheimer's disease-mechanisms, genetics, and therapeutic opportunities.Frontiers in aging neuroscience · 2024Review
- Multi-Index Brain Function-Cognition Correlation in Amnestic Mild Cognitive Impairment: A Resting-State fMRI Study.American journal of Alzheimer's disease and other dementiasArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
introductionThere is a pressing need for non-invasive, cost-effective tools for early detection of Alzheimer's disease (AD).
methodsUsing data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), Cox proportional models were conducted to develop a multimodal hazard score (MHS) combining age, a polygenic hazard score (PHS), brain atrophy, and memory to predict conversion from mild cognitive impairment (MCI) to dementia. Power calculations estimated required clinical trial sample sizes after hypothetical enrichment using the MHS. Cox regression determined predicted age of onset for AD pathology from the PHS.
resultsThe MHS predicted conversion from MCI to dementia (hazard ratio for 80th versus 20th percentile: 27.03). Models suggest that application of the MHS could reduce clinical trial sample sizes by 67%. The PHS alone predicted age of onset of amyloid and tau. DISCUSSION: The MHS may improve early detection of AD for use in memory clinics or for clinical trial enrichment. HIGHLIGHTS: A multimodal hazard score (MHS) combined age, genetics, brain atrophy, and memory. The MHS predicted time to conversion from mild cognitive impairment to dementia. MHS reduced hypothetical Alzheimer's disease (AD) clinical trial sample sizes by 67%. A polygenic hazard score predicted age of onset of AD neuropathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.